Business
Pharma, WHO team up to create permanent ‘pandemic’ market for mandated, experimental vaccines

From LifeSiteNews
By Brenda Baletti, Ph.D., The Defender
Unlimited Hangout journalist Max Jones details how Big Pharma is using the WHO to restructure the drug market, so inadequately tested vaccines and other drugs will face minimal regulation and entire populations can be compelled to take them each time the WHO declares another global pandemic.
Big Pharma and its key investors are rolling out a new strategy — “the full takeover of the public sector, specifically the World Health Organization (WHO), and the regulatory system that now holds the entire market hostage” — according to a new investigative report by Unlimited Hangout’s Max Jones.
What’s behind the new strategy? The pharmaceutical industry is facing a “patent cliff” by 2030, as many of its blockbuster drugs are set to lose their patent protection, placing $180 billion in sales at risk and threatening to topple the industry.
According to Jones, for years, when patents expired on profitable drugs, pharmaceutical giants deployed a “mergers and acquisitions” strategy, buying up smaller drug companies to add to their product portfolios.
As a result, the industry is now dominated by a handful of companies, conventional chemical drugs exist for most health issues, and the regulatory process for new ones has become onerous.
Big Pharma has now pivoted to acquiring biotech and biologic companies, whose products are “more complex, unpredictable and difficult and expensive to make,” than chemical-based medicine, Jones wrote.
Conventional drugs are chemically synthesized and have a known structure according to the U.S. Food and Drug Administration (FDA). Biologics come from living humans, animal or microorganism cells, and are technologically altered to target particular proteins or cells in the immune system. The FDA calls biologics “complex mixtures that are not easily identified or characterized.”
As a drug class, biologics offer an appealing solution to the patent cliff problem, because they can’t be easily replicated like generic versions of conventional drugs.
Instead, producers make “biosimilars,” which unlike genetics can’t simply be interchanged with the original drug during a course of treatment without serious safety risks, according to Jones. And while generics are cheap, biosimilars are still expensive to produce. There also are regulatory hurdles to getting biosimilars to market.
However, Jones wrote, the serious safety issues associated with biologics — the high risk of serious adverse events associated with the COVID-19 vaccine, for example — make it difficult for drugmakers to find commercial success in a conventional regulatory environment.
“Luckily for Big Pharma,” Jones wrote, the WHO and its private backers “are pursuing an unprecedented legal process that would cement loopholes that could solve these significant market challenges of at least some biotechnologies.”
Such loopholes made Pfizer and Moderna’s COVID-19 mRNA vaccines — the paradigmatic example of this new strategy — Big Pharma’s highest-selling annual market success ever.
Distribution of the COVID-19 vaccines to approximately 70% of people globally was possible only because of the “fast-tracked, deregulated development and mandated consumption of the experimental drugs,” Jones wrote.
The industry hopes to replicate that model with other drugs. And it has already begun — last month the Biomedical Advanced Research and Development Authority, or BARDA, gave Moderna $176 million to develop an mRNA bird flu vaccine.
Stakeholders behind the WHO have turned it into an arm of Big Pharma
According to Jones, the process of rapidly developed and mandated experimental drugs was first adopted by the U.S. military for bioweapons threats. Now, it is being internationally legitimized by the WHO through the agency’s revisions to the International Health Regulations (IHR) and its continued attempt to push its pandemic treaty.
The amendments were watered down and the treaty was partially thwarted at the last meeting of the World Health Assembly, which ended on June 1. However, the powers added to the amendments and the language in the treaty WHO and its backers are still hoping to advance next year show the type of biotech pandemic market Big Pharma has in the works.
According to Jones, this market:
Will not be one that depends on the free will of consumers to opt in and out of products — but instead relies on tactics of forced consumption and manipulation of regulatory paradigms.
At the forefront of this push are the WHO’s public-private-partners/private stakeholders, who directly shape and benefit from this policy. Their influence has, in effect, turned the WHO into an arm of Big Pharma, one so powerful that it already demonstrated its ability to morph the entire international regulatory process for the benefit of the pharmaceutical industry during the COVID-19 pandemic.
These stakeholders can wield this power in part because the WHO receives 80% of its funding from private stakeholders.
Those stakeholders include private-sector giants like Bill Gates, his public-private partnership organizations like the Coalition for Epidemic Preparedness Innovations (CEPI) and public-sector bureaucrats, such as Dr. Anthony Fauci and Rick Bright, Ph.D., of BARDA and the Rockefeller Foundation, who have been working for years to create a new system that would speed up vaccine production.
During the COVID-19 pandemic period, even states that lacked legal structures to provide emergency authorization for new drugs created them, using the WHO’s Emergency Use Listing Procedure (EUL) as justification, and aided by the WHO’s COVAX vaccine distribution system. COVAX was co-led by the WHO, Gavi, CEPI and Unicef, which are all backed by Gates.
The goal now, Jones wrote, is to institutionalize the procedures that were put in place globally for COVID-19 to pave the way for a new pandemic market.
The One Health agenda, which requires “full-scale surveillance of the human-animal environment,” both before and during pandemics, is central to this plan, he wrote.
The four pillars of the emerging pandemic market
There are four pillars to the plan for securing this market. The pillars are embodied in the WHO’s recently passed IHR amendments and the proposed pandemic treaty.
1. Biosurveillance of “pathogens with pandemic potential”: The WHO is calling on member states to create infrastructure to conduct biosurveillance on entire populations.
WHO private stakeholders, like the Wellcome Trust and the Bill & Melinda Gates Foundation, have been funding such initiatives for years and continue to be at the forefront of similar initiatives today, Jones wrote.
2. Rapid sharing of data and research: Under the IHR amendments, the WHO’s director-general must provide support for member states’ research and development. In the pending treaty, that would include helping them rapidly share data during a pandemic.
Such sharing should help coordinate global pandemic responses and also “pandemic prevention.” That means building a globally coordinated effort to research and share data on diseases that don’t currently pose a public health threat but are allegedly “likely to cause epidemics in the future.”
The WHO’s announcement last week that it is facilitating data-sharing for a new mRNA bird flu vaccine from Argentina is one example.
Experts have raised concerns that incentivizing such “preventive R&D” could incentivize risky gain-of-function research, Jones wrote.
Jones also noted that it is “highly likely” that the same global organizations that partner with the WHO and are funded by its largest private donors will be the ones doing this research and development on vaccines for “future pathogens with pandemic potential” — and also the ones profiting from it.
3. New regulatory pathways: The WHO is developing new regulatory pathways for unapproved medical products to get to market during pandemic emergencies. The IHR amendments are vague on this, Jones wrote, but the proposed language of the treaty aims to speed up emergency authorizations of WHO-recommended investigational “relevant health products.”
The proposed treaty also seeks to compel member countries to take steps to ensure they have the “legal, administrative and financial frameworks in place to support emergency regulatory authorizations for the effective and timely approval of pandemic-related health products during a pandemic.”
4. Global mandates of unapproved products: The final key element in the Big Pharma-WHO plan to pave the way for a new pandemic market is shoring up the global capacity to mandate unapproved medical products.
According to Jones, in July 2023, the WHO adopted the European Union’s (EU) digital COVID-19 passport system, or the “immunity pass” which recorded people’s vaccination records, negative test results or records of previous infections.
“While a digital vaccine passport does not function as a hard mandate in which every citizen of a given population is forced to take a vaccine, it acts as a conditional mandate — one which offers the illusion of choice, but — in reality — restricts the civil liberties of those who do not comply,” Jones wrote.
The 2005 version of the IHR allowed for travel-based mandates that required proof of vaccination to enter countries when there was a public health risk. The new IHR, Jones wrote, expands on this by detailing the kinds of technology that can be used to check such information during future pandemics.
The WHO also is developing its Global Digital Health Certification Network, which expands the EU digital passport system to a global scale. It will digitize vaccination records and health records and will be “interoperable” with existing networks.
While interoperability makes it possible for decentralized data to be shared globally, Jones wrote, “The UN is seeking to impose digital identification as a ‘human right,’ or rather as a condition for accessing other human rights, for the entire global citizenry by 2030, as established in its Sustainable Development Goal 16.9.”
The initiative seeks to provide people with a “trusted, verifiable way” to prove who they are in the physical world and online.
Verification systems of this size will place the right of citizens to do basic activities — like traveling, eating at a restaurant or working their job — in the hands of governments and potentially employers.
The rights of civilians will be conditional, dictated by data stored in a massive digital hub that is global in its sharing abilities. Not only will domestic governments have access to the health information of their own citizens under this system, but an entire global bureaucracy will as well.
This article was originally published by The Defender — Children’s Health Defense’s News & Views Website under Creative Commons license CC BY-NC-ND 4.0. Please consider subscribing to The Defender or donating to Children’s Health Defense.
Automotive
Auto giant shuts down foreign plants as Trump moves to protect U.S. industry

MxM News
Quick Hit:
Stellantis is pausing vehicle production at two North American facilities—one in Canada and another in Mexico—following President Donald Trump’s announcement of 25% tariffs on foreign-made cars. The move marks one of the first corporate responses to the administration’s push to bring back American manufacturing.
Key Details:
-
In an email to workers Thursday, Stellantis North America chief Antonio Filosa directly tied the production pause to the new tariffs, writing that the company is “continuing to assess the medium- and long-term effects” but is “temporarily pausing production” at select assembly plants outside the U.S.
-
Production at the Windsor Assembly Plant in Ontario will be paused for two weeks, while the Toluca Assembly Plant in Mexico will be offline for the entire month of April.
-
These plants produce the Chrysler Pacifica minivan, the new Dodge Charger Daytona EV, the Jeep Compass SUV, and the Jeep Wagoneer S EV.
Diving Deeper:
On Wednesday afternoon in the White House Rose Garden, President Trump announced sweeping new tariffs aimed at revitalizing America’s auto manufacturing industry. The 25% tariffs on all imported cars are part of a broader “reciprocal tariffs” strategy, which Trump described as ending decades of globalist trade policies that hollowed out U.S. industry.
Just a day later, Stellantis became the first major automaker to act on the new policy, halting production at two of its international plants. According to an internal email obtained by CNBC, Stellantis North American COO Antonio Filosa said the company is “taking immediate actions” to respond to the tariff policy while continuing to evaluate the broader impact.
“These actions will impact some employees at several of our U.S. powertrain and stamping facilities that support those operations,” Filosa wrote.
The Windsor, Ontario plant, which builds the Chrysler Pacifica and the newly introduced Dodge Charger Daytona EV, will shut down for two weeks. The Toluca facility in Mexico, responsible for the Jeep Compass and Jeep Wagoneer S EV, will suspend operations for the entire month of April.
The move comes as Stellantis continues to face scrutiny for its reliance on low-wage labor in foreign markets. As reported by Breitbart News, the company has spent years shifting production and engineering jobs to countries like Brazil, India, Morocco, and Mexico—often at the expense of American workers. Last year alone, Stellantis cut around 400 U.S.-based engineering positions while ramping up operations overseas.
Meanwhile, General Motors appears to be responding differently. According to Reuters, GM told employees in a webcast Thursday that it will increase production of light-duty trucks at its Fort Wayne, Indiana plant—where it builds the Chevrolet Silverado and GMC Sierra. These models are also assembled in Mexico and Canada, but GM’s decision suggests a shift in production to the U.S. could be underway in light of the tariffs.
As Trump’s trade reset takes effect, more automakers are expected to recalibrate their production strategies—potentially signaling a long-awaited shift away from offshoring and toward rebuilding American industry.
Business
‘Time To Make The Patient Better’: JD Vance Says ‘Big Transition’ Coming To American Economic Policy

JD Vance on “Rob Schmitt Tonight” discussing tariff results
From the Daily Caller News Foundation
By Hailey Gomez
Vice President JD Vance said Thursday on Newsmax that he believes Americans will “reap the benefits” of the economy as the Trump administration makes a “big transition” on tariffs.
The Dow Jones Industrial Average dropped 1,679.39 points on Thursday, just a day after President Donald Trump announced reciprocal tariffs against nations charging imports from the U.S. On “Rob Schmitt Tonight,” Schmitt asked Vance about the stock market hit, asking how the White House felt about the “Liberation Day” move.
“We’re feeling good. Look, I frankly thought in some ways it could be worse in the markets, because this is a big transition. You saw what the President said earlier today. It’s like a patient who was very sick,” Vance said. “We did the operation, and now it’s time to make the patient better. That’s exactly what we’re doing. We have to remember that for 40 years, we’ve been doing this for 40 years.”
“American economic policy has rewarded people who ship jobs overseas. It’s taxed our workers. It’s made our supply chains more brittle, and it’s made our country less prosperous, less free and less secure,” Vance added.
Vance recalled that one of his children had been sick and needed antibiotics that were not made in the United States. The Vice President called it a “ridiculous thing” that some medicines invented in the country are no longer manufactured domestically.
“That’s fundamentally what this is about. The national security of manufacturing and making the things that we need, from steel to pharmaceuticals, antibiotics, and so forth, but also the good jobs that come along when you have economic policies that reward investing in America, rather than investing in foreign countries,” Vance said.
WATCH:
With a baseline 10% tariff placed on an estimated 60 countries, higher tariffs were applied to nations like China and Israel. For example, China, which has a 67% tariff on U.S. goods, will now face a 34% tariff from the U.S., while Israel, which has a 33% tariff, will face a 17% U.S. tariff.
“One bad day in the stock market, compared to what President Trump said earlier today, and I think he’s right about this. We’re going to have a booming stock market for a long time because we’re reinvesting in the United States of America. More importantly than that, of course, the people in Wall Street have done well,” Vance said.
“We want them to do well. But we care the most about American workers and about American small businesses, and they’re the ones who are really going to benefit from these policies,” Vance said.
The number of factories in the U.S., Vance said, has declined, adding that “millions of workers” have lost their jobs.
“My town [Middletown, Ohio], where you had 10,000 great American steel workers, and my town was one of the lucky ones, now probably has 1,500 steel workers in that factory because you had economic policies that rewarded shipping our jobs to China instead of investing in American workers,” Vance said. “President Trump ran on changing it. He promised he would change it, and now he has. I think Americans are going to reap the benefits.”
-
Business2 days ago
California planning to double film tax credits amid industry decline
-
2025 Federal Election5 hours ago
Canada Continues to Miss LNG Opportunities: Why the World Needs Our LNG – and We’re Not Ready
-
Catherine Herridge2 days ago
FBI imposed Hunter Biden laptop ‘gag order’ after employee accidentally confirmed authenticity: report
-
Business1 day ago
B.C. Credit Downgrade Signals Deepening Fiscal Trouble
-
COVID-191 day ago
Trump’s new NIH head fires top Fauci allies and COVID shot promoters, including Fauci’s wife
-
2025 Federal Election1 day ago
Will Four More Years Of Liberals Prove The West’s Tipping Point?
-
Freedom Convoy1 day ago
Freedom Convoy leaders Tamara Lich, Chris Barber found guilty of mischief
-
Business23 hours ago
Trump’s ‘Liberation Day’ – Good News for Canadian Energy and Great News for WCSB Natural Gas